This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of -25% and 9.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Cresco Labs (CRLBF) is Placed Before Q1 Earnings
by Zacks Equity Research
Cresco Labs' (CRLBF) rationalization and optimization efforts are expected to have had a positive impact on the company's first-quarter margins, profitability and cash flow.
Should SNDL (SNDL) be in Your Portfolio Ahead of Q1 Earnings?
by Riya Anand
SNDL's (SNDL) first-quarter performance is expected to benefit from reduced cost expenses and expansion into the liquor retail segment.
Should You Buy Hims & Hers Health (HIMS) Ahead of Q1 Earnings?
by Urmimala Biswas
Hims & Hers Health's (HIMS) first-quarter earnings are expected to have benefited from its strategy of placing its solutions at attractive price points.
Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Gritstone bio (GRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength in Kidney Care Likely to Aid DaVita's (DVA) Q1 Earnings
by Zacks Equity Research
Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the first quarter.
Down -63.39% in 4 Weeks, Here's Why Gritstone bio (GRTS) Looks Ripe for a Turnaround
by Zacks Equity Research
Gritstone bio (GRTS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Gritstone (GRTS) Plummets 58% in a Week: Here's Why
by Zacks Equity Research
Gritstone (GRTS) plunges after a mid-stage study evaluating its personalized cancer vaccine in certain patients with colorectal cancer failed to achieve its primary endpoint.
Do Options Traders Know Something About Gritstone bio (GRTS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Gritstone bio (GRTS) stock based on the movements in the options market lately.
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 27.78% and 116.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -1.49% and 37.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Gritstone bio Inc. (GRTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gritstone bio Inc. (GRTS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 6.25% and 38.93%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Janux Therapeutics, Inc. (JANX) delivered earnings and revenue surprises of 14.29% and 21.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 17.02% and 4.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Gritstone bio Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 3.23% and 38.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -7.02% and 112.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 10.26% and 22.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gritstone bio Inc. (GRTS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Gritstone bio Inc. (GRTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gritstone bio Inc. (GRTS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 15% and 117.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of -3.03% and 16.38%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. (ANAB) Soars 6.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.